

Immuno-Oncology Summit 2017

Centre de Recherche des Cordeliers (CRC) – Paris

July 6, 2017

Morning session –	Morning session –
Amphithéâtre Farabeuf	Amphithéâtre Bilsky-Pasquie

			/ !
08:00 a.m.	Welcome	08:00 a.m.	Welcome
08:20 a.m.	Synergy between radiotherapy and immunotherapy Silvia Chiara Formenti, M.D., Weill Cornell Medicine, New York, USA	08:20 a.m.	Challenges in colorectal cancer: from vaccines to macrophage repolarization Niels Halama, M.D., German Cancer Research Center (DKFZ), Heidelberg, Germany
08:45 a.m.	Melanoma: immunotherapy in advanced melanoma and in the adjuvant setting Alexander Eggermont, M.D., Ph.D., Gustave Roussy Cancer Center, Villejuif, France	08:45 a.m.	Immune therapies in phase 1 trials Jean-Charles Soria, M.D., Ph.D., Gustave Roussy Cancer Center, Villejuif, France Oncolytic viruses: T VEC and others
09:10 a.m.	Immune checkpoint inhibition in lung cancer	09.10 a.m.	Igor Puzanov, M.D., Roswell Park Cancer Institute, Buffalo, USA
09:35 a.m.	Roy S. Herbst, M.D., Yale University, New Haven, USA Predictors of response to immune	09:35 a.m.	Cancer vaccines in HPV malignancies Cornelia Trimble, M.D., Ph.D., Johns Hopkins Outpatient Center, Baltimore, USA
09.33 a.iii.	checkpoint blockade	10:00 a.m.	Case study and open discussion
	Jennifer Wargo, M.D., Ph.D.,	10:20 a.m.	Coffee break
	MD Anderson Cancer Center, Houston, USA	10:40 a.m.	Co-stimulation agonists via CD137,
10:00 a.m.	Case study and open discussion		OX40, GITR and CD27 for immunotherapy
10:20 a.m.	Coffee break		of cancer
10:40 a.m.	NK cell-based therapy Eric Vivier, Vet, Ph.D., Center of Immunology Marseille-Luminy, France		Ignacio Melero, M.D., Ph.D., Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
11:05 a.m.	Immunotherapy of gliomas Michael Platten, M.D., Ph.D., German Cancer Research Center (DKFZ), Heidelberg, Germany	11:05 a.m.	Assessing T cell receptor affinity and avidity against tumor antigens Mathilde Allard, Ph.D.,
11:30 a.m.	PDL-1 and other immunological		University of Lausanne, Switzerland
	diagnosis tools Janis M. Taube, M.D., Ph.D., Johns Hopkins University School of Medicine, Baltimore, USA	11:30 a.m.	PD1 checkpoint blockade in melanoma: from monotherapy to combination therapies Dirk Schadendorf, M.D.,
11:55 a.m.	Case study and open discussion		University of Essen, Germany
12:15 p.m.	Lunch break	11:55 a.m.	Case study and open discussion
		12:15 p.m.	Lunch break

This program is supported by independent educational grants from Miltenyi Biotec GmbH, Incyte Corporation, Servier, Lytix Biopharma AS, and the European Academy of Tumor Immunology. Jointly provided by Postgraduate Institute for Medicine and KC Consulting.

Target audience: This activity is targeted to medical oncologists/hematologist-oncologists who actively manage, treat and follow-up with patients with various malignancies being treated with immuno-oncology anticancer agents, including combination cancer immunotherapies (CCIT).

Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

July 6, 2017

Afternoon session – Amphithéâtre Farabeuf

01:30 p.m. Regulatory T cells: their role, mechanism

of action, and impact on cancer

Dario Vignali, Ph.D.,

University of Pittsburgh, USA

01:55 p.m. CD8⁺ T cells in immunotherapy,

radiotherapy, and chemotherapy

Weiping Zou, M.D., Ph.D.,

University of Michigan, Ann Arbor, USA

02:20 p.m. Purinergic receptors: novel targets

for cancer immunotherapy

Michèle Teng, Ph.D.,

QIMR Berghofer Medical Research Institute,

Brisbane, Australia

02:55 p.m. Biology of myeloid-derived

suppressor cells

Dmitry I. Gabrilovich, M.D., Ph.D., The Wistar Institute, Philadelphia, USA

03:20 p.m. Coffee break

03:40 p.m. The impact of the intestinal microbiota

in therapeutic responses against cancer

Laurence Zitvogel, M.D., Ph.D., Gustave Roussy Cancer Center,

Villejuif, France

04:05 p.m. Side effects of immunotherapy

with checkpoint inhibitors Paolo Ascierto, M.D., Ph.D.,

National Tumor Institute, Napoli, Italy

04:30 p.m. Case study and open discussion

05:00 p.m. End of session

Afternoon session – Amphithéâtre Bilsky-Pasquier

01:30 p.m. Tumor-targeted antibodies

Aurélien Marabelle, M.D., Ph.D., Gustave Roussy Cancer Center,

Villejuif, France

01:55 p.m. Plasmacytoid DC/Regulatory T cell

interactions at the center of an

immunosuppressive network in breast

and ovarian tumors

Christophe Caux, Ph.D.,

Centre Léon Bérard, Lyon, France

02:20 p.m. Mutant epitopes in cancer*

Markus Maeurer, M.D., Ph.D.,

Karolinska Institute, Stockholm, Sweden

02:55 p.m. PD1 blockade in renal cell carcinoma*

Lisa Derosa, M.D.,

Gustave Roussy Cancer Center,

Villejuif, France

03:20 p.m. Coffee break

03:40 p.m. Immune monitoring of blood and tumor

microenvironment
Daniel Speiser, Ph.D.,


University of Lausanne, Switzerland

04:05 p.m. Case study and open discussion

04:35 p.m. End of session

*CME credit will not be offered for this presentation.





For more information, please visit https://tinyurl.com/k3ausgk

July 7, 2017

Morning session – Amphithéâtre Farabeuf

08:00 a.m.	Welcome	08:00 a.m.	Welcome
08:20 a.m.	Innate immune receptors in the regulation of tumor immunity Tadatsugu Taniguchi, Ph.D., University of Tokyo, Japan	08:20 a.m.	The human tumor microenvironment Wolf Herman Fridman, M.D., Ph.D., and Catherine Sautès Fridman, M.D., Ph.D., Cordeliers Research Center, Paris, France
08:45 a.m.	Peptide-based therapeutic cancer vaccines* Cornelis Melief, M.D., Ph.D., Leiden University Medical Center,	08:45 a.m.	The secrets of T cell polarization Lionel Apetoh, Ph.D., INSERM, Centre Georges-François Leclerc, University of Dijon, France
09:10 a.m.	The Netherlands Immunotherapy for prostate cancer: An evolving landscape Charles Drake, M.D., Ph.D., Columbia University Medical Center, New York, USA	09:10 a.m.	Immunogenic stress and death of cancer cells in natural and therapy-induced immunosurveillance Guido Kroemer, M.D., Ph.D., Gustave Roussy Cancer Center, Villejuif, France
09:35 a.m.	Cancer immunosurveillance by natural killer cells and other innate lymphoid cells Mark J. Smyth, Ph.D., QIMR Berghofer Medical Research Institute,	09:35 a.m.	Effect of pharmaceutical compounds on myeloid-derived supressor cells (MDSCs) François Ghiringhelli, M.D., Ph.D., INSERM, Centre Georges-François Leclerc, University of Dijon, France
10:00 a.m.	Brisbane, Australia Current status of onco-immunology in hematologic cancers David Ghez, M.D., and Bertrand Routy, M.D., Gustave Roussy Cancer Center,	10:00 a.m.	Resident memory T cells play a key role in the efficacy of cancer vaccines Eric Tartour, M.D., Ph.D., Hôpital Européen Georges Pompidou, Paris, France
	Villejuif, France	10:25 a.m.	Coffee break
10:25 a.m. 10:45 a.m.	Coffee break Local immunotherapies of cancer Joshua Brody, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, USA	10:45 a.m.	Challenges of onco-immunology for breast and ovarian cancers Emmanuela Romano, M.D., Ph.D., Institut Curie Research Center, Paris, France
11:10 a.m.	IDO- and TDO-based inhibition in cancer George Prendergast, M.D., Ph.D., Lankenau Institute for Medical Research,	11:10 a.m.	BCG and Anti-PDL-1 Ab in bladder cancers Yohann Loriot, M.D., Gustave Roussy Cancer Center, Villejuif, France
	Philadelphia, USA	11:35 a.m.	Case study and open discussion
11:35 a.m.	Case study and open discussion	12:00 p.m.	Concluding remarks
12:00 p.m. 12:20 p.m.	End of session Lunch break		Wolf Herman Fridman, M.D., Ph.D., Cordeliers Research Center, Paris, France and Pedro Romero, M.D., Université de Lausanne, Switzerland
*CME credit will r	not be offered for this presentation.	12:20 p.m.	Lunch break

Morning session -

Amphithéâtre Bilsky-Pasquier





For more information, please visit https://tinyurl.com/k3ausgk

July 7, 2017

Afternoon session** – Amphithéâtre Farabeuf

Landscape of immuno-oncology in the next 5 years

Please join us for a special series of presentations from leading experts in academia and industry to explore the challenges and opportunities ahead in the exciting field of immuno-oncology.

As these presentations will feature speakers from industry, continuing medical education credit will not be provided.

01:30 p.m. Welcome

Guido Kroemer, M.D., Ph.D., Gustave Roussy Cancer Center,

Villejuif, France

01:40 p.m. The mechanistic basis of anti-PD-L1/PD-1-

based immunotherapy Ira Mellman, Ph.D.,

Genentech, South San Francisco, USA

02:05 p.m. Mechanisms of protective

immunotherapy Glenn Dranoff, M.D., Novartis, Cambridge, USA

02:30 p.m. Integration of science and technology

innovation: a modular approach to

oncology cell therapy Cedrik Britten, M.D.,

GlaxoSmithKline (GSK), Stevenage, UK

02:55 p.m. Coffee break

03:15 p.m. Cancer immunotherapy:

What's on the horizon for patients?

John C. Reed, M.D., Ph.D., Roche, Basel, Switzerland 03:40 p.m. Active immunization using a novel

heteroclitic peptide mixture against WT1 (galinpepimut-S): Preliminary evidence of multifunctional cross-epitope T-cell reactivity and summary of clinical

research efforts

Nicholas J. Sarlis, M.D., Ph.D.,

Sellas Life Sciences Group, New York, USA

04:05 p.m. Enabling CAR T cell therapy through

closed-system manufacturing

Andrew Kaiser, Ph.D., Miltenyi Biotec, Bergisch Gladbach,

Germany

04:30 p.m. Concluding remarks and

awards ceremony

Guido Kroemer, M.D., Ph.D., Gustave Roussy Cancer Center,

Villejuif, France


Laurence Zitvogel, M.D., Ph.D., Gustave Roussy Cancer Center,

Villejuif, France

This program is supported by ${\sf GlaxoSmithKline}$ and an anonymous donation.

**The July 7 afternoon session of the meeting is not supported by educational grants and CME credit will not be provided.





For more information, please visit https://tinyurl.com/k3ausgk

Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and KC Consulting, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.